an organism is likely to be clinically significant (26). We set out to review HHV-6 data from the local diagnostic microbiology 1 1 6 laboratory, to determine the patterns of clinical testing for HHV-6. Second, we 1 1 7 screened randomly selected CSF and respiratory samples using PCR and 1 1 8
NGS in a small pilot study to ascertain the extent to which this virus can be 1 1 9
detected in routine samples. Together, these aim to describe the distribution 1 2 0 of HHV-6 in local clinical samples, and to evaluate the contribution made by 1 2 1 different diagnostic tools, thereby informing ongoing development of 1 2 2 laboratory protocols for diagnosis. used for viral sequencing studies (ID numbers prefixed VS). We used GraphPad Prism v.6.0f for statistical analysis with Fisher's Exact ii. For respiratory samples, the patient had a clinical history of 1 7 0 immunocompromise and/or was on the intensive care unit. Genomics and assembled using SSE v1.2 (29). We selected a random subset of 20 samples for Illumina sequencing.
1 9 2
Methods are described in detail in another manuscript (30). During the three-year study period, our clinical laboratory received 85 1 9 7 samples for HHV-6 testing ( Fig 1A; suppl data set 1). In total, 41 patients were (37%) were PCR positive at ≥ 1 timepoint ( Fig 1A) . Of seven samples that 2 0 5
were subtyped, all were HHV-6B. Positive HHV-6 status was not statistically associated with age, sex, or 2 0 8 haematological malignancy (Table 1) . There was a borderline association with 2 0 9
both GvHD and CNS disease (both p=0.05; Table 1 ; Fig. 2A and B ), but this is 2 1 0 difficult to interpret as patients in these groups are more likely to be selected 2 1 1 for HHV6 testing. On multiple logistic regression analysis, there was no 2 1 2 relationship between HHV-6-positivity and any other characteristic (Table 1) .
In this cohort, 23/41 (56%) of patients died, at a median age of 56 years. patients with HHV6 detected in the CSF died ( Fig 2C) . We did not have 2 1 9
sufficient clinical data to determine cause of death, and HHV6 may be a 2 2 0 bystander in this complex cohort. 
Quantification of HHV-6 viral load in blood and CSF (HHV cohort)
2 2 3 HHV-6 DNA was quantified in 23 samples from ten patients ( Fig 2C) . The 2 2 4 levels varied from below the threshold for accurate quantification, to patient 2 2 5
HHV-012 with >1.0x10 6 copies/ml in blood and 2.0x10 8 DNA copies/ml in CSF, suggesting CiHHV-6. Patient HHV-007, an adult with haematological 2 2 7 malignancy, had HHV-6 DNA detected in both blood and CSF (9x10 4 DNA 2 2 8 copies/ml vs. 3x10 5 copies/ml, respectively). This patient had limbic 2 2 9 1 1 encephalitis, and the raised HHV-6 titre in CSF compared to blood is in 2 3 0 keeping with a localized CNS pathology caused by the virus. location, documented co-infection in multiple regression analysis). 
Screening laboratory samples for HHV-6 by PCR (VS cohort)
2 3 9
We screened CSF (n=100) and respiratory (n=100) samples for herpesvirus The overall HHV-6 prevalence of 4% in this random group of samples is 2 5 0 significantly lower than the 33% rate obtained from the samples in which the low numbers of reads leading us to classify them as equivocal (Fig 4A,B) . Conversely, in four samples where HHV-6 was detected by NGS, only one of 2 8 4 these was positive by PCR. to date that describes a metagenomic approach to the diagnosis of HHV-6 2 9 2 infection (6). Although HHV-6 can reactivate in the context of any critical cohort, suggest that we should consider lowering our threshold for testing in absence of an alternative explanation), then serial testing may be helpful. This study was not designed to evaluate the use or outcome of antiviral 3 0 5 therapy as this information could not robustly be captured retrospectively.
0 6
There are some data to suggest good outcomes from treatment of with the two HHV-6 subtypes. For samples with low HHV-6 copy numbers, PCR is anticipated to be more 3 1 7 sensitive than NGS; this is illustrated by two samples that tested positive by testing positive for HHV-6 DNA was higher by NGS than by PCR. This may at 3 2 0 least in part be accounted for by PCR using highly degenerate herpesvirus 3 2 1 primers, followed by sequencing primers that have a higher degree of 3 2 2 sequence homology for HHV-6B than HHV-6A (28). In screening by NGS, we identified HHV-6 in 4/20 (20%) samples, using a 3 2 5 combination of read numbers and genome coverage to infer positivity (33). Multiple considerations feed into the interpretation of NGS data (Fig 5) . The broad-spectrum antibiotics. The number of clinical requests for HHV-6 testing each year is small, even in Although it is doubtless at times a benign passenger, HHV-6 is indeed role in other syndromes, including respiratory infections in children. Metagenomic approaches to clinical diagnostics are accelerating, and as 3 5 1 additional data become available, increasing insights will be gained into the 3 5 2
interpretation of these results. None to declare. transplantation. Biology of blood and marrow transplantation : journal of 5 2 8
